Day One Biopharmaceuticals Raises Revenue Guidance, Driving Stock Upward

Day One Biopharmaceuticals shares are trading higher after the company reported strong third quarter financial results and raised its full-year 2025 net product revenue guidance to $145 to $150 million, highlighting the robust performance of its product OJEMDA.